Hebrew University Researchers to Collaborate With GRAIL on Methylation Data from Multiple Cell Types to understand How to interpret the Source of blood-based Signals
Yissum, the Technology Transfer Company of The Hebrew University of Jerusalem, announced a strategic collaboration with GRAIL, Inc., a healthcare company whose mission is to detect
Oramed Initiates a Food Effect Study for its Oral Insulin Capsule ORMD-0801
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that it has initiated a
BrainsWay and Cohen Veterans Bioscience Collaborating in Biomarker Research for Post Traumatic Stress Disorder
Unique Biomarkers Sought to Enable Personalized Medicine Approach for Treatment of Post Traumatic Stress Disorder (PTSD) Brainsway Ltd.(BRIN.TA), a leader in the advanced non-invasive treatment
InnovationQuarter (NL) visits the Hebrew University BioGiv “Excubator” Infrastructure Center
June 7, 2018 – InnovationQuarter (NL) visited the @BioGiv “Excubator” Infrastructure Center of the Hebrew University at the Hitech Village on the Givat Ram Campus. The
VideoTherapy to present at the Summer Expo June 28, Cleveland, Ohio
In Spring 2018, Plug and Play Cleveland Innovation Platform began it’s first inaugural Health & Wellness accelerator program. Plug and Play evaluated hundreds of startups from across
Thomas Jefferson University announces Global Center in Jerusalem
June 6, 2018 – Thomas Jefferson University announced Tuesday, June 6 2018, the opening of the Jefferson Israel Center in Jerusalem before a packed audience at
Jerusalem based 6Degrees “Computer Mouse for Amputees”
May 28, 2018 – 6Degrees is developing a unique algorithm that will be embedded within a line of products; the first of which is Crescent,
Jerusalem-based Kitov Announces Commercialization Agreement for their Drug against Osteoarthritis Pain Consensi™ with China
June 3, 2018 – Kitov Pharma Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that the Company has signed a definitive license and
Jerusalem-based Omnix Medical is developing Novel Antibiotic Agents Against Resistant Pathogenic Bacterial Strains
Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix focuses on ESKAPE pathogens: K.
